Several experimental strategies can restore or replace p53 function in cells carrying TP53 mutations, ranging from small molecules that refold the damaged protein to gene-editing tools that correct the DNA itself. None has yet become a standard cancer treatment, but one approach, a compound called eprenetapopt (APR-246), reached late-stage clinical trials with response rates above 60% in certain blood cancers. The field is moving fast, with at least half a dozen distinct strategies under active investigation, each suited to different mutation types and cancer settings.
Why Mutant p53 Is Uniquely Hard to Fix
The p53 protein acts as one of the cell’s central emergency responders. When DNA sustains serious damage, p53 can halt cell division, initiate repair, or trigger the cell’s self-destruct sequence. Losing that function is bad enough, but TP53 mutations create an additional problem. The mutant protein does not just sit there doing nothing. It can actively interfere with any remaining normal p53 in the cell through what researchers call a dominant-negative effect, where the faulty protein binds to and disables normal copies.
A study in myeloid malignancies found that this dominant-negative effect, not some exotic new cancer-driving ability, was the primary reason TP53 missense mutations gave blood cancer cells a survival advantage after DNA damage.1PubMed Central. A dominant-negative effect drives selection of TP53 missense mutations in myeloid malignancies Some mutant p53 proteins may also acquire entirely new pro-cancer activities, a phenomenon called gain-of-function, though the relative importance of gain-of-function versus dominant-negative effects is debated and may depend on cancer type.2PubMed. Mutant p53 oncogenicity: dominant-negative or gain-of-function? Either way, the upshot is the same: simply giving a cell extra normal p53 may not be enough if the mutant version is still around sabotaging things.
The mutations themselves also come in different flavors that respond differently to treatment. “Contact” mutations change one of the amino acids that directly touches DNA, while “structural” mutations distort the protein’s overall three-dimensional shape.3Oncogene. TP53 DNA contact mutations are selectively associated with allelic loss and have a strong clinical impact in head and neck cancer A drug designed to prop up a misfolded protein might work well against structural mutations but do little for a contact mutant whose shape is fine but whose DNA-gripping surface is broken. This is why there is no single magic bullet and why researchers are pursuing multiple strategies simultaneously.
Small Molecule Reactivators
The most clinically advanced attempt to restore mutant p53 is eprenetapopt, originally known as APR-246. Inside the body, the drug converts into a reactive molecule called MQ that chemically latches onto specific cysteine residues in the p53 protein’s core, essentially propping the misfolded structure back into a functional shape.4bioRxiv. APR-246 reactivates mutant p53 by targeting cysteines 124 and 277 Think of it as inserting a splint into a broken bone so the limb can bear weight again.
In a phase II trial combining eprenetapopt with the chemotherapy drug azacitidine, 55 patients with TP53-mutant myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) were treated. About 71% responded overall, with 44% achieving complete remission. Among MDS patients specifically, the complete remission rate was 50%. Roughly a third of all patients achieved what is called complete molecular remission, meaning the TP53-mutant cells dropped to very low levels. Median overall survival was about 11 months, with responding patients living significantly longer than nonresponders.5PubMed Central. Eprenetapopt (APR-246) and Azacitidine in TP53-Mutant Myelodysplastic Syndromes
A French study using the same combination found similar trends: an overall response rate of 62% in MDS patients, with nearly half achieving complete remission. About 73% of responders cleared their TP53-mutant cells to very low levels. Neurological side effects were more prominent in this trial, occurring in about 40% of patients, though they resolved when doses were adjusted.6PubMed Central. Eprenetapopt Plus Azacitidine in TP53-Mutated Myelodysplastic Syndromes and Acute Myeloid Leukemia: A Phase II Study by the Groupe Francophone des Myélodysplasies (GFM)
These results were encouraging for a disease where TP53-mutant patients historically have very poor outcomes, but eprenetapopt subsequently struggled in a larger randomized phase III trial. It did not meet its primary endpoint, which has cooled some of the initial enthusiasm. Researchers are now looking at whether it might work better in different combinations or in patients selected more narrowly by mutation type.
Zinc Metallochaperones
A subset of TP53 mutations causes the protein to lose its grip on zinc, a metal atom that is essential for p53 to fold correctly and bind DNA. Without zinc, the protein essentially collapses into a non-functional shape. Researchers have developed small molecules called zinc metallochaperones that act as delivery escorts, ferrying zinc directly to the zinc-binding pocket of these mutant proteins and restoring their ability to fold properly.7PubMed Central. Thiosemicarbazones Functioning as Zinc Metallochaperones to Reactivate Mutant p53 This approach is elegant because it targets the root cause of misfolding in zinc-deficient mutants, but it is naturally limited to that particular class of mutations. Work on zinc metallochaperones remains preclinical.
Breaking Up Mutant p53 Clumps
Some mutant p53 proteins do not just misfold individually; they clump together into amyloid-like aggregates, similar in concept to the protein tangles seen in neurodegenerative diseases. These aggregates can trap any remaining normal p53 and drag it into the dysfunctional mass, amplifying the damage. A cell-penetrating peptide called ReACp53 was designed to disrupt these aggregates. In ovarian cancer organoids, a lab model grown from actual patient tumors, ReACp53 broke apart the clumps and restored p53’s tumor-suppressing activity.8PubMed Central. A Designed Inhibitor of p53 Aggregation Rescues p53 Tumor Suppression in Ovarian Carcinomas
The same peptide showed activity against prostate cancer cells carrying p53 mutations. In those experiments, ReACp53 not only freed the clumped p53 but restored its ability to enter the nucleus and turn on the genes that trigger cell death. It also slowed tumor growth in mouse models.9PubMed Central. Therapeutic potential of ReACp53 targeting mutant p53 protein in CRPC Like zinc metallochaperones, anti-aggregation peptides remain in early-stage research, but they illustrate a creative angle: you do not always have to fix the protein if you can stop it from making things worse.
Destroying the Mutant Protein Instead of Fixing It
If the mutant p53 protein cannot be repaired, an alternative is to get rid of it entirely. This is the logic behind PROTACs (proteolysis-targeting chimeras), engineered molecules that act as molecular matchmakers. One end of the PROTAC grabs the mutant p53 protein; the other end recruits the cell’s own protein-disposal machinery. The cell’s proteasome then chews up the mutant protein like any other piece of cellular garbage.
Recent work has produced PROTACs targeting the R175H mutation, one of the most common TP53 hotspot mutations. One group built a peptide-based PROTAC that successfully directed R175H mutant p53 to the proteasome for degradation.10ACS Omega. Promising Proteolysis-Targeting Chimera for Mutant p53-R175H Another team used an engineered DNA aptamer as the mutant-p53-grabbing end and showed their degrader could destroy R175H protein while leaving normal p53 untouched.11Science Bulletin. An engineered DNA aptamer-based PROTAC for precise therapy of p53-R175H hotspot mutant-driven cancer That selectivity is critical: you want to eliminate the harmful mutant without wiping out whatever normal p53 the cell might still produce.
The PROTAC approach has the potential advantage of working regardless of whether the mutation is structural or contact, since it destroys the protein rather than trying to reshape it. But removing mutant p53 only helps if the cell still has a functional TP53 gene on its other chromosome, or if mutant p53 destruction is combined with a way to resupply normal p53.
Gene Editing and mRNA Replacement
The most direct way to “reverse” a TP53 mutation is to rewrite the DNA itself. Gene-editing technologies are beginning to show this is feasible. Research using base editing, a CRISPR-derived technique that changes individual DNA letters without cutting both strands of the double helix, has corrected several TP53 hotspot mutations in cancer cell lines from different tissue types. Correcting these mutations restored conserved tumor-suppressive gene programs regardless of what other mutations were present in the cell.12PubMed Central. A base editing platform for the correction of cancer driver mutations unmasks conserved p53 transcription programs
Prime editing, a newer and more versatile CRISPR variant, has also been applied to TP53 hotspot mutations including R175H, R248Q/W, R273H/C, and R282W in colorectal cancer models.13PubMed. Precision prime editing of TP53 mutations for functional tumor suppression in colorectal cancer These are among the most commonly mutated positions in human cancer, so the ability to repair them even in laboratory settings is significant.
The enormous practical hurdle with gene editing is delivery. Getting editing machinery into every cancer cell in a patient’s body, while avoiding off-target changes in healthy tissues, remains one of the hardest problems in medicine. This is why mRNA-based approaches are also under investigation: rather than rewriting the faulty gene, you flood the cell with messenger RNA encoding normal p53, temporarily resupplying the protein. Nanoparticle delivery systems carrying synthetic p53 mRNA have slowed the growth of p53-deficient liver and lung cancer cells in lab studies by reactivating cell-cycle arrest and programmed cell death.14PubMed Central. Synthetic mRNA nanoparticle-mediated restoration of p53 tumor suppressor sensitizes p53-deficient cancers to mTOR inhibition Nanoparticle-delivered p53 gene therapy has also inhibited tumors and improved survival in animal models, though systemic delivery still needs improvement to match the effectiveness of direct injection into tumors.15PubMed Central. Nanoparticle-mediated p53 gene therapy for tumor inhibition
Strategies That Work Around the Mutation
Not every approach to dealing with a TP53 mutation involves restoring the protein itself. Several strategies exploit the consequences of p53 loss instead.
In cancers that still carry a normal TP53 gene but keep p53 protein levels low through overactive degradation, MDM2 inhibitors can help. MDM2 is the protein that normally tags p53 for destruction, keeping its levels in check when it is not needed. Drugs like nutlin-3a block MDM2, allowing p53 to accumulate and activate. This works specifically in tumors with wild-type p53, not those with mutations in the gene itself, since there is no point in stabilizing a broken protein.16Dove Medical Press. Activation of wild-type p53 by MDM2 inhibitors: a new strategy for lymphoma treatment
Synthetic lethality is a fundamentally different tactic. When p53 is broken, cancer cells lose one of their key DNA-damage checkpoints and become more dependent on remaining backup checkpoints to survive. WEE1 is one such backup checkpoint, and many TP53-mutant cancers upregulate it to cope with the resulting replication stress.17PubMed. WEE1 inhibition in cancer therapy: Mechanisms, synergies, preclinical insights, and clinical trials Blocking WEE1 with inhibitors forces these cells into division before their DNA is repaired, triggering a catastrophic form of cell death. In non-small cell lung cancer cells carrying both KRAS and TP53 mutations, WEE1 inhibition pushed cells into this kind of lethal crisis.18Cell Reports Medicine. WEE1 inhibition enhances apoptosis in KRAS-mutant non-small cell lung cancer with TP53 mutations by inducing mitotic catastrophe The beauty of synthetic lethality is that the mutation itself becomes the vulnerability.
Immunotherapy offers yet another angle. Because mutant p53 proteins contain amino acid sequences that differ from normal p53, the immune system can theoretically recognize fragments of the mutant protein displayed on the cancer cell’s surface. Researchers have identified T-cell receptors that specifically target the R248Q mutation when it is presented by a particular immune molecule. Engineered T cells carrying this receptor killed tumor cells with that exact mutation in the lab and shrank tumors in mice transplanted with human TP53-mutant cancer tissue.19JCI Insight. T cell receptor–engineered T cells targeting the TP53R248Q neoantigen elicit antitumor effects in human cancer models The selectivity was impressive: the engineered T cells ignored normal p53 and even other mutations at the same position. The limitation is that each T-cell receptor targets one specific mutation-and-immune-molecule combination, so scaling this to the hundreds of known TP53 mutations would require an enormous library of receptors.
The Special Case of Inherited TP53 Mutations
Most TP53 mutations in cancer arise during a person’s lifetime in individual tumor cells. But some people are born with a TP53 mutation in every cell of their body, a condition called Li-Fraumeni syndrome. These individuals face extraordinarily high lifetime cancer risks, often developing multiple cancers starting in childhood or young adulthood. Treatment is complicated by the fact that radiation therapy, a standard cancer weapon, can actually backfire in Li-Fraumeni patients. Germline TP53 mutations make cells more resistant to radiation’s intended killing effect while simultaneously raising the risk of new radiation-induced cancers, with an estimated 30% increased risk of secondary malignancies in the radiation field.20PubMed Central. Clinical Features and Treatment Strategies of Li‐Fraumeni Syndrome Patients With Inherited TP53 Mutations
For Li-Fraumeni patients, the dream of reversing TP53 mutations takes on a different character. Gene editing every cell in the body is not currently possible, so the more immediate hope lies in surveillance protocols that catch cancers early and in targeted therapies for the specific tumors that arise. Some of the p53-reactivating strategies discussed above could eventually be relevant for treating Li-Fraumeni-associated cancers, though none has been tested specifically in that population yet.
Post-Translational Modifications Add Another Layer
Even if you fix or replace the p53 protein, its behavior is heavily influenced by chemical tags that cells attach to it after production. The normal p53 protein can be chemically modified at over 60 of its 393 amino acid positions, and these modifications help determine when p53 is active, how stable it is, and which genes it turns on. Most mutant p53 proteins can still be modified at the same positions as normal p53, which means these tags can alter mutant p53’s behavior in unpredictable ways.21PubMed Central. Mutant TP53 posttranslational modifications: challenges and opportunities This is both a challenge and an opportunity. It means that some drugs might be able to influence mutant p53’s harmful activities by changing how it gets tagged, but it also means that reactivating a mutant protein might not produce perfectly normal p53 behavior if the modification landscape has shifted.
What Elephants Reveal About p53 Redundancy
One of the more fascinating detours in p53 research involves elephants. Despite being massive animals with trillions of cells and long lifespans, elephants develop cancer at surprisingly low rates. The explanation appears to be that elephants carry about 20 copies of the TP53 gene, compared to the single copy in humans. This expansion evolved alongside the increase in body size in the elephant lineage and appears to give elephant cells a hair-trigger response to DNA damage.22PubMed Central. TP53 copy number expansion is associated with the evolution of increased body size and an enhanced DNA damage response in elephants Most of these extra copies are retrogenes, processed copies of the gene that were reinserted into the genome, and researchers are still working out exactly how they contribute to cancer protection and whether they play additional roles in elephant biology like reproduction.23PubMed. Peto’s paradox and elephant TP53 retrogenes: cancer or reproduction?
The elephant example underscores a broader point: nature’s solution to p53 vulnerability was not to make the protein indestructible but to add redundancy. Humans, stuck with just one copy per chromosome, have to solve the problem the hard way, through medicine. But the fact that evolution independently arrived at “more p53 equals better cancer protection” validates the premise behind every restoration strategy discussed above. Getting functional p53 back into cancer cells, whether by refolding the protein, editing the gene, delivering mRNA, or engineering immune cells to kill mutant-p53-bearing tumors, is a biologically sound goal. The challenge has always been the engineering, not the biology.